Connect
MJA
MJA

The power of one and its cost

Robert J Norman
Med J Aust 2011; 195 (10): 564-565. || doi: 10.5694/mja11.11283
Published online: 21 November 2011

The case for continued public funding of IVF using single embryo transfer

Assisted reproductive technologies, including in-vitro fertilisation (IVF), are now mainstream treatments in Australia, strongly supported by public opinion and accessible to most patients via adequate Medicare funding. Over the past 30 years, the growth in uptake of IVF in this country has been remarkable, with nearly 4% of all live births resulting from this mode of conception.1 This is associated with a loss of stigma surrounding infertility and the increased acceptability of IVF as a treatment option. Technologies such as intracytoplasmic sperm injection, use of donor gametes and embryos, preimplantation genetic diagnosis, improved access through an expansion of clinics, and the rapid commercialisation of the industry have all combined to expand services available to patients.

  • Robert J Norman1,2

  • 1 Robinson Institute, University of Adelaide, Adelaide, SA.
  • 2 Fertility SA, Adelaide, SA.


Competing interests:

I and my institution have received research and travel grants and honoraria from companies producing gonadotrophin hormones used in IVF. I am a shareholder in a reproductive medicine company, Fertility SA.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.